Previous 10 | Next 10 |
home / stock / mdgef / mdgef news
The following slide deck was published by Medigene AG in conjunction with this Read more ...
Ultra-thinly traded Medigene AG ( OTCPK:MDGEF +35% ) is up, albeit on a miniscule 1,400 shares, on the heels of topline data from a Phase 1/2 clinical trial evaluating its autologous dendritic cell vaccine in 20 acute myeloid leukemia (AML) patients. More news on: Medigene AG, Hea...
The following slide deck was published by Medigene AG in conjunction with this Read more ...
Medigene AG (MDGEF) Q3 2019 Results Earnings Conference Call November 13, 2019, 08:00 AM ET Company Participants Gary Waanders - Vice President of Investor Relations Dolores Schendel - Chief Executive Officer and Chief Scientific Officer Axel Malkomes - Chief Financial Officer an...
The following slide deck was published by Medigene AG in conjunction with their 2019 Q3 earnings Read more ...
Medigene AG ( OTCPK:MDGEF ): Q3 GAAP EPS of -€0.23. Revenue of €1.3B (-30.9% Y/Y) Press Release More news on: Medigene AG, Earnings news and commentary, Tech stocks news, ,
August saw some portfolio restructuring with markets dropping heavily on escalating U.S.-China trade relations before staging a strong comeback at the end of the month. It's always exciting to review the past month at the beginning of the next one in order to track the development of passive...
The summer holiday and earnings season is nearing its close, and overall, it has been a great one. July saw record portfolio performance despite the reignited trade war when Trump surprisingly exited U.S.-China trade negotiations. However, markets were rattled in early August when Trump announ...
Medigene AG (MDGEF) Q2 2019 Results Earnings Conference Call August 7, 2019 9:00 AM ET Company Participants Julia Hofmann - Head of Public and Investor Relations Dolores Schendel - Chief Executive Officer and Chief Scientific Officer Axel Malkomes - CFO and Chief Business Dev...
The following slide deck was published by Medigene AG in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the presentation of two posters...
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued...
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead ...